Galton/BlueStone/Morons:
Here's a phone number, email address, and a website......
Wednesday June 24, 9:31 am Eastern Time
Company Press Release
Jenner Biotherapies Receives Japanese Patent Covering Core Technology
for Cancer Vaccines
SAN RAMON, Calif.--(BW HealthWire)--June 24, 1998--Jenner Biotherapies Inc. today announced it has been issued
Japan patent No. 020652/1989 8/469,309 which covers vectors, compounds and methods for expression of a human
adenocarcinoma antigen known as KSA (or GA733-2).
Jenner is using this core technology in the development of the company's therapeutic vaccine, OncoVax-CL(TM), designed to
delay or prevent the recurrence of cancer.
The company is engaged in U.S. clinical trials of OncoVax-CL, for therapy of colorectal cancer. The vaccine also has potential
for therapy of lung, prostate, ovarian, and pancreatic cancer.
''This is a broad patent relative to the Pacific Rim market,'' said Anthony E. Maida, chief executive officer. ''It extends the
patent protection Jenner has previously secured in the United States, Europe, and Australia.''
Jenner Biotherapies of San Ramon, Calif., is involved in the development and clinical evaluation of immunotherapies for patients
with cancer. The focus is on treating patients who have a minimal tumor burden in an effort to slow disease progression and
improve survival and quality of life in patients with cancer. The company has three product platforms for cancer
immunotherapy; one involving the use of recombinant vaccines, a second involving macrophage activators, and a third involving
a vaccine adjuvant.
Jenner Biotherapies is located at 2010 Crow Canyon Place, Suite 100, San Ramon, Calif., 94583-1344; phone
510/824-3150; FAX 510/824-3151; email amaida@jennerbio.com; WEB site jennerbio.com. |
